BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1438418)

  • 1. Bone marrow purging with antisense oligodeoxynucleotides.
    Gewirtz AM
    Prog Clin Biol Res; 1992; 377():215-24; discussion 225-6. PubMed ID: 1438418
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroblastoma purging by immunorosette depletion.
    Slaper-Cortenbach IC; de Vries-van Rossen A; Huijbens RJ; van Leeuwen EF; Figdor CG
    Prog Clin Biol Res; 1992; 377():147-62. PubMed ID: 1438411
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of purging clonogenic leukemia cells using ether lipid and hyperthermia for autologous bone marrow transplantation.
    Min WS; Park HM; Han CH; Park JW; Kim CC; Kim DJ
    Prog Clin Biol Res; 1992; 377():87-95. PubMed ID: 1438449
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of Ethiofos on cytotoxicity of pharmacological purging protocols used for autologous marrow grafts in acute lymphoblastic leukemia.
    Skala JP; Rogers PC; Chan KW; Rodriguez WC
    Prog Clin Biol Res; 1992; 377():57-62. PubMed ID: 1332075
    [No Abstract]   [Full Text] [Related]  

  • 5. Antisense oligonucleotide OL (1) p53 for in vitro purging of autologous bone marrow in acute myelogenous leukemia.
    Bishop MR; Warkentin PI; Jackson JD; Bayever E; Iversen PL; Whalen VI; Lastovica J; Haines K; Kessinger A
    Prog Clin Biol Res; 1994; 389():183-7. PubMed ID: 7700901
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro effects of Ilmofosine on acute lymphoblastic leukemia cells and on normal hemopoietic cells.
    Skala JP; Rogers PC; Chan KW; Khangura SS; Rodriguez WC
    Prog Clin Biol Res; 1992; 377():63-9. PubMed ID: 1438445
    [No Abstract]   [Full Text] [Related]  

  • 7. Bone marrow purging in patients with refractory cancer.
    Meagher RC; Stevens DA; Herzig GP; Fay JW; Harden EA; Montes VM; Heye MM; Herzig RH
    Prog Clin Biol Res; 1992; 377():281-7. PubMed ID: 1438426
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of mafosfamide on the clonogenic cells in precursor B acute lymphoblastic leukemia: significance for ex vivo purging of bone marrow.
    Kramer B; Makrynikola V; Bradstock K
    Prog Clin Biol Res; 1992; 377():41-7. PubMed ID: 1438438
    [No Abstract]   [Full Text] [Related]  

  • 9. Purging of acute lymphoblastic leukemia by long-term marrow culture.
    Douay L; Ozsahin H; Barbu V; Fabrega S; Giarratana MC; Da WM; Allieri A; Gorin NC
    Prog Clin Biol Res; 1992; 377():205-13; discussion 214. PubMed ID: 1438417
    [No Abstract]   [Full Text] [Related]  

  • 10. Regulatory activity of endogenous MIP-1 alpha in long-term cultures of human marrow.
    Cashman JD; Eaves AC; Wolpe S; Eaves CJ
    Prog Clin Biol Res; 1994; 389():261-8. PubMed ID: 7700910
    [No Abstract]   [Full Text] [Related]  

  • 11. Deferoxamine as a purging agent for autologous bone marrow grafts in neuroblastoma.
    Skala JP; Rogers PC; Chan KW; Chao HY; Rodriguez WC
    Prog Clin Biol Res; 1992; 377():71-8. PubMed ID: 1438447
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotides.
    Gewirtz AM
    Bone Marrow Transplant; 1994; 14 Suppl 3():S57-61. PubMed ID: 7697011
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of DNAse on the detection of residual malignant cells by polymerase chain reaction after immunologic purging of autologous bone marrow grafts.
    Vervoordeldonk SF; Merle PA; Steenbergen EJ; van Leeuwen EF; von dem Borne AE; Slaper-Cortenbach IC
    Prog Clin Biol Res; 1994; 389():601-9. PubMed ID: 7700926
    [No Abstract]   [Full Text] [Related]  

  • 14. [Role of marrow purging].
    Rizzoli V; Carlo-Stella C; Mangoni L
    Haematologica; 1991 Jun; 76 Suppl 3():311-20. PubMed ID: 1684346
    [No Abstract]   [Full Text] [Related]  

  • 15. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the protection of murine bone marrow stem cells by WR-2721 during in vitro treatment with mafosfamide.
    Jiang R; Bony V; Lopez M
    Prog Clin Biol Res; 1994; 389():23-9. PubMed ID: 7700906
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular approaches to purging of chronic myelogenous leukemia marrow in autologous transplantation.
    Yuan T; Zhou YQ; Herst CV; Reading C; Ellersen D; Etkin M; Khouri I; Kantarjian H; Talpaz M; Deisseroth A
    Prog Clin Biol Res; 1992; 377():227-30. PubMed ID: 1438419
    [No Abstract]   [Full Text] [Related]  

  • 18. The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems.
    Roots-Weiss A; Papadimitriou C; Serve H; Hoppe B; Koenigsmann M; Reufi B; Oberberg D; Thiel E; Berdel WE
    Bone Marrow Transplant; 1997 Jun; 19(12):1239-46. PubMed ID: 9208119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.
    Gidáli J; Fehér I
    Bone Marrow Transplant; 1992 Dec; 10(6):479-83. PubMed ID: 1490197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of mafosfamide (ASTA-Z-7654) on the clonogenic cells in precursor-B acute lymphoblastic leukaemia: significance for ex vivo purging of bone marrow for autologous transplantation.
    Makrynikola V; Kabral A; Bradstock KF
    Bone Marrow Transplant; 1991 Nov; 8(5):351-5. PubMed ID: 1768969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.